Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses

Vaccine

Volumn 18, Issue 9-10, 1999, Pages 899-906

  Treanor, John J ^a   Kotloff, Karen ^b   Betts, Robert F ^a   Belshe, Robert ^c   Newman, Fran ^c   Iacuzio, Dominick ^d   Wittes, Janet ^e   Bryant, Martin ^f  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e University of Iowa   (United States)

^f MEDIMMUNE   (United States)

Author keywords

Clinical studies; Influenza; Vaccines

Indexed keywords

INFLUENZA VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ADMINISTRATION, INTRANASAL; ADULT; COLD; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; VACCINES, COMBINED; VACCINES, SYNTHETIC;

EID: 0032702094     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00334-5     Document Type: Article

References (25)

1. Murphy B.R. Use of live, attenuated cold-adapted influenza A reassortant virus vaccines in infants, children, young adults, and elderly adults. Infect. Dis. Clin. Pract. 2:1993;176-181.
2. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., Bernstein D.E., Hayden F.G., Kotloff K., Zangwill K., Iacuzio D., Wolff M. The efficacy of live attenuated cold-adapted trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 358:1998;1405-1412.
3. Edwards K.M., Dupont W.D., Westrich M.K., Plummer W.D.J., Palmer P.S., Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J. Infect. Dis. 169:1994;68-76.
4. Maassab H.F., DeBorde D.C. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine. 3:1985;335-369.
5. Treanor J., Dolin R., Betts R.F., Erb S., Roth F., Reichman R.C. Intranasal interferon as prophylaxis against experimentally induced influenza in humans. J. Infect. Dis. 156:1987;379-383.
6. Murphy B.R., Phelan M.E., Nelson D.L., Yarchoan R., Tierney E.L., Alling D.W., Chanock R.M. Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J. Clin. Microbiol. 13:1981;554-560.
7. Phelan M.A., Mayner R.E., Bucher D.J., Ennis F.A. Purification of influenza virus glycoproteins for the preparation and standardization of immunological potency testing reagents. J. Biol. Standard. 8:1980;233-242.
8. Clements M.L., O'Donnell S., Levine M.M., Chanock R.M., Murphy B.R. Dose response of A/Alaska/6/77 cold-adapted reassortant vaccine virus in adult volunteers; role of local antibody in resistance to infection with vaccine. Infect. Immun. 40:1983;1044-1051.
9. Murphy B.R., Clements M.L., Madore H.P., Steinberg J., O'Donnell S., Betts R., Demico D., Reichman R.C., Dolin R., Maasaab H.F. Dose response of cold-adapted, reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers. J. Infect. Dis. 149:1984;814-816.
10. Keitel W.A., Couch R.B., Quarles J.M., Cate T.R., Baxter B., Maassab H.F. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J. Infect. Dis. 167:1993;305-311.
11. Atmar R.L., Keitel W.A., Cate T.R., Quarles J.M., Couch R.B. Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults. J. Infect. Dis. 172:1995;253-257.
12. Wright P.F., Okabe N., McKee K.T. Jr., Massab H.B., Karzon D.T. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J. Infect. Dis. 146:1982;71-79.
13. Gruber W.C., Kirschner K., Tollefson S., Thompson J., Reed G., Edwards K.M., Wright P.F. Comparison of monovalent and trivalent live attenuated influenza vaccines in young children. J. Infect. Dis. 168:1993;53-60.
14. Swierkosz E.M., Newman F.K., Anderson E.L., Nugent S.L., Mills G.B., Belshe R.B. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children. J. Infect. Dis. 169:1994;1121-1124.
15. Gruber W.C., Belshe R.B., King J.C., Treanor J.J., Piedra P.A., Wright P.F., Reed G.W., Anderson E., Newman F. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. J. Infect. Dis. 173:1996;1313-1319.
16. Clements M.L., Betts R.F., Murphy B.R. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet. 1:1984;704-708.
17. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J. Clin. Microbiol. 23:1986;73-76.
18. Clements M.L., Subbarao E.K., Fries L.F., Karron R.A., London W.T., Murphy B.R. Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers. J. Clin. Microbiol. 30:1992;655-662.
19. Youngner J.S., Treanor J.J., Betts R.F., Whitaker-Dowling P. Effect of simultaneous administration of cold-adapted influenza A virus on clinical manifestations of experimental wild-type influenza A virus infection in humans. J. Clin. Microbiol. 32:1994;750-754.
20. Hayden F.G., Tunkel A.R., Treanor J.J., Betts R.F., Allerheiligen S., Harris J. Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans. Antimicrob. Agents Chemother. 38:1994;1178-1181.
21. Hayden F.G., Treanor J.J., Betts R.F., Lobo M., Esinhart J.D., Hussey E.K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA. 275:1996;295-299.
22. Murphy B.R., Chalhub E.G., Nusinoff S.R., Kasel J., Chanock R.M. Temperature-sensitive mutants of influenza virus III. Further characterization of the ts-1[E] influenza A recombinant (H3N2) in man. J. Infect. Dis. 128:1973;479-487.
23. Treanor J.J., Roth F.K., Betts R.F. Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults. J. Clin. Microbiol. 28:1990;596-599.
24. Clements M.L., Snyder M.H., Sears S.D., Maassab H.F., Murphy B.R. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus in adult volunteers. J. Infect. Dis. 161:1990;869-877.
25. Sears S.D., Clements M.L. Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob. Agents Chemother. 31:1987;1470-1473.